Population pharmacokinetics of APOMINE™: A meta-analysis in cancer patients and healthy males

British Journal of Clinical Pharmacology

Volumn 58, Issue 2, 2004, Pages 142-155

  Bonate, Peter L ^a   Floret, Simon ^b   Bentzen, Craig ^b  

^a ILEX Products   (United States)

^b ILEX Oncology Research   (Switzerland)

Author keywords

Clinical trial simulation; Induction; Influence analysis; Monte Carlo simulation; NONMEM; Saturable absorption; Solid tumours

Indexed keywords

2 (3,5 DI TERT BUTYL 4 HYDROXYPHENYL) 1,1 ETHANEBISPHOSPHONIC ACID TETRAISOPROPYL ESTER; BISPHOSPHONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BAYES THEOREM; BODY WEIGHT; CANCER PATIENT; CLINICAL TRIAL; COMPUTER SIMULATION; COVARIANCE; DISTRIBUTION VOLUME; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG HALF LIFE; FOOD DRUG INTERACTION; FOOD INTAKE; HUMAN; MALE; META ANALYSIS; MONTE CARLO METHOD; NORMAL HUMAN; POPULATION MODEL; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; SOLID TUMOR; STATISTICAL ANALYSIS; STEADY STATE; VALIDATION PROCESS;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DIPHOSPHONATES; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, CHEMICAL; MONTE CARLO METHOD; NEOPLASMS;

EID: 3843133122     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2004.02111.x     Document Type: Article

References (20)

1. Roitelman J, Massen D, Avner R, Ammon-Zuffery C, Perez A, Guyon-Gellini Y, Bentzen C, Niesor EJ. Apomine, a novel hypocholesterolemic agent, accelerates degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and stimulates low density lipoprotein receptor activity. J Biol Chem 2004; 279: 6465-73.
2. Flach J, Antoni I, Villemin P, Bentzen CL, Niesor EJ. The mevalonate/isoprenoid pathway inhibitor apomine (SR-45023A) is antiproliferative and induces apoptosis similar to farnesol. Biochem Biophys Res Comms 2000; 270: 240-6.
3. Alberts DS, Hallum AV III, Stratton-Custis M, et al. Phase I pharmacokinetic trial and correlative in vitro phase II tumor kinetic study of Apomine (SR-45023A), a novel oral biphosphonate anticancer drug. Clin Cancer Res 2001; 7: 1246-50.
4. Guyon-Gellin Y, Latin P, Vollemin P, Niesor EJ. Apomine, a novel bone anabolic agent, stimulates bone formation and is hypocholesterolemic in mice. J Bone Mineral Res 2003; 17(Suppl 1): S376.
5. Higaki K, Yamashita S, Amidon GL. Time-dependent oral absorption models. J Pharmacokinetics Pharmacodynamics 2001; 28: 109-28.
6. Hassan M, Svensson USH, Ljungman P, et al. A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients. Br J Clin Pharmacol 1999; 48: 669-77.
7. Kerbusch T, Huitema ADR, Ouwerkerk J, Keizer HJ, Mathot RAA, Schellens JHM. Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach. Br J Clin Pharmacol 2000; 49: 555-61.
8. Rostami-Hodjegan A, Wolff K, Hay AWM, Raistrick D, Calvert R, Tucker GT. Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes. Br J Clin Pharmacol 1999; 48: 43-52.
9. Roberts MS, Magnusson BM, Burczynski FJ, Weiss M. Enterohepatic circulation: physiological, pharmacokinetic, and clinical implications. Clin Pharmacokinet 2002; 41: 751-90.
10. Ploeger B, Mensinga T, Sips A, Meulenbelt J, DeJongh J. A human physiologically-based model for glycyrrhzic acid, a compound subject to presystemic metabolism and enterohepatic cycling. Pharm Res 2000; 17: 1516-25.
11. Walsh TJ, Jackson AJ, Lee JW, et al. Dose-dependent pharmacokinetics of amphotericin B lipid complex in rabbits. Antimicrob Agents Chemother 2000; 44: 2068-76.
12. Wasjima T, Yano Y, Oguma T. A pharmacokinetic model for analysis of drug disposition profiles undergoing enterohepatic circulation. J Pharm Pharmacol 2002; 54: 929-34.
13. Jackson JE. A User's Guide to Principal Components. New York: John Wiley and Sons, Inc. 1991.
14. Karlis D, Saporta G, Spinakis A. A simple rule for the selection of principal components. Comms Statistics Series - Theory Meth 2003; 32: 643-66.
15. Wagner JG. Pharmacokinetics for the pharmaceutical scientist. Lancaster PA. Technomic Publishing Company, 1993.
16. Israili ZH, Dayton PG. Human alpha-1-glycoprotein and its interactions with drugs. Drug Metab Rev 2001; 33: 161-235.
17. Ohnhaus EE, Park BK. Measurement of urinary 6β-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone, and rifampicin. Eur J Clin Pharmacol 1979; 15: 139-45.
18. Park BK, Breckenridge AM. Clinical implications and enzyme induction and enzyme inhibition. Clin Pharmacokinet 1981; 6: 1-24.
19. Krzanowski WJ. Principles of Multivariate Analysis. A User's Perspective. Oxford UK, Oxford University Press, 2000.
20. Zwick WR, Velicer WF. Comparison of five rules for determining the number of components to retain. Psychol Bull 2003; 99: 432-44.